Following the philosophy of "Precise Products, Predictable Effects, Health Protection", Kexing Biopharm is devoted to promoting the R&D of quality biopharmaceutical products with improved clinical value, acting as the safeguard of human's health.
-
1989
Shenzhen Kexing Bioproducts Co., Ltd., was established as an industrial base for interferon production.
-
1996
"Human Interferon α1b for Injection" (SINOGEN) was officially approved for production as Class I biological products.
-
1997
Shandong Kexing Bioproducts Co., Ltd. was established as an industrial platform for recombinant human erythropoietin.
-
1998
"Human Erythropoietin Injection (CHO Cell)" (EPOSINO) was officially approved for production as Class II biological products.
-
2000
Shenzhen Sinovac was recognized by the Ministry of Science and Technology as the "Industrialization Base of National 863 Plan Achievement"
-
2001
"Human Granulocyte Colony-stimulating Factor Injection"(WHITE-C) was officially approved for production.
-
2002
Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule, Live (CLOBICO) was officially approved for production.
-
2009
The EPO agent not containing albumin obtained the certificate of invention patent (patent No. ZL200610146206.0).
-
2014
We integrated the traditional Chinese medicine business focusing on KEHUANG CAPSULE around hepatopathy treatment.
-
2017
Our technology center was ratified as the "Shandong Provincial Enterprise-level Technology Center"
-
2018
Our technology center was ratified as the "Jinan Protein Therapeutics Engineering Laboratory".
-
2019
We launched the slogan "Precise Products, Predictable Effects, Health Protection" and the new logo.
-
2019
The company was restructured into Kexing Biopharmaceutical Co., Ltd. (Kexing Biopharm).
-
2020
Our technology center was ratified as the "Shandong Protein Therapeutics Engineering Laboratory".
-
2020
Our technology center was ratified as the "Guangdong Gene Engineering Recombinant Protein Therapeutics Engineering Technology Center".
-
2020
The company successfully landed on the A-share technology innovation board with the stock code of 688136, becoming the leader of high quality biologicals.
-
2020
The company was approved to set up the "Shenzhen postdoctoral innovation practice base".
-
2021
Kexing Biopharm signed a Drug Cooperation Agreement with Haichang Biotech to obtain the commercial license of HC007 (a complex preparation for injection, a generic drug of a broad-spectrum anticancer drug) in all regions except the US.
Scan Code Consultation
